LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies: For further information please contact: LungLife AI, Inc. www.lunglifeai.com Paul Pagano, CEO via investors@lunglifeai.com Click here to download […]
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the resignation of James McCullough, as a non-executive director of the company, with effect from 24 October 2024. James McCullough has taken the decision to step down from the Board to focus on his Executive role at Renalytix plc. Following this […]
LungLife AI licensure/accreditation information posted here.